Page
%P
![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Chapter and Conference Paper
Phase I Clinical Studies of Tumor Necrosis Factor in Patients with Advanced Cancer
Tumor necrosis factor (TNF), a macrophage-derived polypeptide, was initially described by Carswell and coworkers at Sloan-Kettering as the agent that produced hemorrhagic necrosis of certain transplanted sarco...
-
Article
Chemotherapy of non-small cell lung cancer: Clinical trials at the Memorial Sloan-Kettering Cancer Center
Bronchogenic carcinoma is one of the most difficult and pressing problems in cancer therapy. Overall survival of 799 primary cases at Memorial Sloan-Kettering Cancer Center was 7.8%, reflecting the advanced na.....